Prohibitin attenuates colitis-associated tumorigenesis in mice by modulating p53 and STAT3 apoptotic responses

Cancer Research

Volumn 72, Issue 22, 2012, Pages 5778-5789

  Kathiria, Arwa S ^a   Neumann, William L ^b   Rhees, Jennifer ^a   Hotchkiss, Erin ^a   Cheng, Yulan ^c   Genta, Robert M ^b   Meltzer, Stephen J ^c   Souza, Rhonda F ^b   Theiss, Arianne L ^a  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROHIBITIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BCL 2 GENE; BCL XL GENE; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROHIBITIN GENE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STAT3 GENE; TRANSGENIC MOUSE; TUMOR VASCULARIZATION; ULCERATIVE COLITIS; WILD TYPE;

ANIMALS; APOPTOSIS; CACO-2 CELLS; COLITIS; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; REPRESSOR PROTEINS; STAT3 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84869224215     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0603     Document Type: Article

References (46)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78.
2. Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 1994;35:1590-2.
3. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15:103-13.
4. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008;118:560-70.
5. McClung JK, Jupe ER, Liu XT, Dell'Orco RT. Prohibitin: potential role in senescence, development, and tumor suppression. Exp Gerontol 1995;30:99-124.
6. Wang S, Fusaro G, Padmanabhan J, Chellappan SP. Prohibitin colocalizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene 2002;21:8388-96.
7. Wang S, Zhang B, Faller DV. Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth. EMBO J 2002;21:3019-28.
8. Hsieh SY, Shih TC, Yeh CY, Lin CJ, Chou YY, Lee YS. Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics 2006;6:5322-31.
9. Theiss AL, Idell RD, Srinivasan S, Klapproth JM, Jones DP, Merlin D, et al. Prohibitin protects against oxidative stress in intestinal epithelial cells. FASEB J 2007;21:197-206.
10. Theiss AL, Jenkins AK, Okoro NI, Klapproth JM, Merlin D, Sitaraman SV. Prohibitin inhibits tumor necrosis factor alpha-induced nuclear factor-kappa B nuclear translocation via the novel mechanism of decreasing importin alpha3 expression. Mol Biol Cell 2009;20:4412-23.
11. Theiss AL, Laroui H, Obertone TS, Chowdhury I, Thompson WE, Merlin D, et al. Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitis. Inflamm Bowel Dis 2011;17:1163-76.
12. Theiss AL, Vijay-Kumar M, Obertone TS, Jones DP, Hansen JM, Gewirtz AT, et al. Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflammation in mice. Gastroenterology 2009;137:199-208, 08 e1-6.
13. Tsai HW, Chow NH, Lin CP, Chan SH, Chou CY, Ho CL. The significance of prohibitin and c-Met/hepatocyte growth factor receptor in the progression of cervical adenocarcinoma. Hum Pathol 2006;37:198-204.
14. Ren HZ, Wang JS, Wang P, Pan GQ, Wen JF, Fu H, et al. Increased expression of prohibitin and its relationship with poor prognosis in esophageal squamous cell carcinoma. Pathol Oncol Res 2010;16:515-22.
15. Kang X, Zhang L, Sun J, Ni Z, Ma Y, Chen X, et al. Prohibitin: a potential biomarker for tissue-based detection of gastric cancer. J Gastroenterol 2008;43:618-25.
16. Sato T, Sakamoto T, Takita K, Saito H, Okui K, Nakamura Y. The human prohibitin (PHB) gene family and its somatic mutations in human tumors. Genomics 1993;17:762-4.
17. Nan Y, Yang S, Tian Y, Zhang W, Zhou B, Bu L, et al. Analysis of the expression protein profiles of lung squamous carcinoma cell using shot-gun proteomics strategy. Med Oncol 2009;26:215-21.
18. Wu TF, Wu H, Wang YW, Chang TY, Chan SH, Lin YP, et al. Prohibitin in the pathogenesis of transitional cell bladder cancer. Anticancer Res 2007;27:895-900.
19. Gregory-Bass RC, Olatinwo M, Xu W, Matthews R, Stiles JK, Thomas K, et al. Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis. Int J Cancer 2008;122:1923-30.
20. Coates PJ, Nenutil R, McGregor A, Picksley SM, Crouch DH, Hall PA, et al. Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. Exp Cell Res 2001;265:262-73.
21. Dart DA, Spencer-Dene B, Gamble SC, Waxman J, Bevan CL. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours. Endocr Relat Cancer 2009;16:1157-69.
22. Ko KS, Tomasi ML, Iglesias-Ara A, French BA, French SW, Ramani K, et al. Liver-specific deletion of prohibitin 1 results in spontaneous liver injury, fibrosis, and hepatocellular carcinoma in mice. Hepatology 2010;52:2096-108.
23. Liu T, Tang H, Lang Y, Liu M, Li X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 2009;273:233-42.
24. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007;133:1869-81.
25. Clapper ML, Cooper HS, Chang WC. Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions. Acta Pharmacol Sin 2007;28:1450-9.
26. Chang WC, Coudry RA, Clapper ML, Zhang X, Williams KL, Spittle CS, et al. Loss of p53 enhances the induction of colitis-associated neoplasia by dextran sulfate sodium. Carcinogenesis 2007;28:2375-81.
27. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-9.
28. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010;138:2101-14, e5.
29. Huerta S, Goulet EJ, Livingston EH. Colon cancer and apoptosis. Am J Surg 2006;191:517-26.
30. Qiu W, Carson-Walter EB, Kuan SF, Zhang L, Yu J. PUMA suppresses intestinal tumorigenesis in mice. Cancer Res 2009;69:4999-5006.
31. Downward J. How BAD phosphorylation is good for survival. Nat Cell Biol 1999;1:E33-5.
32. Atreya R, Neurath MF. Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr Drug Targets 2008;9:369-74.
33. Neumann H, Vieth M, Langner C, Neurath MF, Mudter J. Cancer risk in IBD: how to diagnose and how to manage DALM and ALM. World J Gastroenterol 2011;17:3184-91.
34. Feagins LA, Souza RF, Spechler SJ. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 2009;6:297-305.
35. Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994;107:369-78.
36. Lassmann S, Schuster I, Walch A, Gobel H, Jutting U, Makowiec F, et al. STAT3mRNAand protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation. J Clin Pathol 2007;60:173-9.
37. Du W, Hong J, Wang YC, Zhang YJ, Wang P, Su WY, et al. Inhibition of JAK2/STAT3 signaling induces colorectal cancer cell apoptosis via mitochondrial pathway. J Cell Mol Med. 2011 Nov 2. [Epub ahead of print].
38. Artal-Sanz M, Tavernarakis N. Prohibitin and mitochondrial biology. Trends Endocrinol Metab 2009;20:394-401.
39. Rastogi S, Joshi B, Fusaro G, Chellappan S. Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent mechanism. J Biol Chem 2006;281:2951-9.
40. Sharma A, Qadri A. Vi polysaccharide of Salmonella typhi targets the prohibitin family of molecules in intestinal epithelial cells and suppresses early inflammatory responses. Proc Natl Acad Sci U S A 2004;101:17492-7.
41. Kathiria AS, Butcher LD, Feagins LA, Souza RF, Boland CR, Theiss AL. Prohibitin 1 modulates mitochondrial stress-related autophagy in human colonic epithelial cells. PLoS One 2012;7:e31231.
42. Czarnecka AM, Campanella C, Zummo G, Cappello F. Mitochondrial chaperones in cancer: from molecular biology to clinical diagnostics. Cancer Biol Ther 2006;5:714-20.
43. Joshi B, Rastogi S, Morris M, Carastro LM, DeCook C, Seto E, et al. Differential regulation of human YY1 and caspase 7 promoters by prohibitin through E2F1 and p53 binding sites. Biochem J 2007;401:155-66.
44. Chander H, Halpern M, Resnick-Silverman L, Manfredi JJ, Germain D. Skp2B attenuates p53 function by inhibiting prohibitin. EMBO Rep 2009;11:220-5.
45. Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S. Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem 2003;278:47853-61.
46. Chander H, Halpern M, Resnick-Silverman L, Manfredi JJ, Germain D. Skp2B overexpression alters a prohibitin-p53 axis and the transcription of PAPP-A, the protease of insulin-like growth factor binding protein 4. PLoS One 2011;6:e22456.